Professor James is Professor of Clinical Oncology at the University of Birmingham and Consultant in Clinical Oncology at the Queen Elizabeth Hospital specialising in urological oncology. He qualified in 1983 from St Bartholomew’s Hospital with the principal class prize in internal medicine. After general medical training in London and Brussels, oncology training was undertaken at Hammersmith, the Royal Marsden, St Mary’s and St Bartholomew’s Hospitals and the Cancer Institute, Tokyo. He has been based in Birmingham since 1994.

Current research is focused on clinical trials in urological tumours and information provision over the Internet. In 1994 he co-founded the leading patient website CancerHelp UK (www.cancerhelp.org.uk). Trials of the Birmingham-developed CTL102 adenovirus in prostate cancer have been successfully completed and a follow-on trial funded by the MRC is in preparation. In the urological clinical trials field, he is currently chief investigator on 2 large trials in prostate cancer STAMPEDE and TRAPEZE. He is also chief investigator on the recently closed chemoradiotherapy trial BC2001 which is the largest randomised trial of radiotherapy in bladder cancer. Previously completed work includes being chief investigator on the EPOC trial comparing ZD4054 with placebo in early metastatic hormone refractory prostate cancer as well as UK Chief Investigator for the pivotal TAX327 study which lead to the licensing of Docetaxel in prostate cancer.

Publications

Automatic PubMed Search for Prof James